Skip to main content
    A

    AN2 Therapeutics Inc (ANTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.23
    -0.24 (-5.37%)

    Market Cap: $172.64M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    AN2 Therapeutics Inc (ANTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    AN2 Therapeutics (ANTX) has a market cap of $172.64M and an enterprise value of $152.44M. Its share count is up 52.31% from a year earlier. It holds $20.21M more cash than debt, 11.70% of its market cap.

    Total Valuation

    Enterprise value is 11.70% below the market cap, as cash exceeds debt.

    Market Cap$172.64M
    Enterprise Value$152.44M
    Latest price (Nov 17, 2026)$4.23

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.02% in the quarter ended Sep 30, 2026 and grew 24.31% a year over 2 years.

    Shares Outstanding46.11M
    Shares Change (YoY)+52.31%
    Shares Change (QoQ)+3.02%
    Share Count Growth (2Y CAGR)+24.31%

    Price Statistics

    The stock is up 271.05% over 52 weeks and trades 7.03% below its 50-day average.

    Beta (1Y)0.60
    52-Week Change+271.05%
    1-Month Change+25.52%
    3-Month Change-29.03%
    6-Month Change-7.03%
    Total Return (1Y)+271.05%
    Total Return (3Y CAGR)-36.02%
    Return vs SPY (1Y)+266.12%
    Max Drawdown (1Y)-46.34%
    Max Drawdown (3Y)-95.45%
    Sharpe Ratio (1Y)1.19
    Correlation with SPY (1Y)0.07
    50-Day Average$4.55
    200-Day Average$4.26
    52-Week Range$1.00 to $7.19
    RSI (14 Days)48.1
    Average Volume (20 Days)254.72K

    Price chart

    Financial Position

    Current assets cover 10.48x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio10.48x
    Quick Ratio10.48x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -46.19% and return on assets is -42.56% over the last 12 months.

    Return on Equity (ROE)-46.19%
    Return on Assets (ROA)-42.56%
    ROA (5Y Average)-46.42%
    ROIC (5Y Average)-45.86%

    Scores

    ANTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$37.44M
    Pretax Income-$34.88M
    Net Income-$34.88M
    Reported EPS (TTM)-$0.93

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 92.14% of the $81.95M in total assets.

    Cash and Equivalents$20.21M
    Total Debt$0
    Net Cash$20.21M
    Net Cash Per Share$0.44
    Working Capital$59.49M
    Shareholder Equity$75.51M
    Book Value Per Share$1.64
    Total Assets$81.95M
    Total Liabilities$6.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$30.41M
    FCF Per Share-$0.81
    Depreciation and Amortization$494.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-35.29%
    Tangible Book Per Share Growth (2Y CAGR)-35.29%

    Revenue and profit by year

    Dividends and Yields

    ANTX does not pay a dividend.

    Buyback Yield-15.35%
    Shareholder Yield-15.35%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ANTX

    What is ANTX's market cap?

    AN2 Therapeutics has a market cap of $172.64M. Its enterprise value, which adds debt and subtracts cash, is $152.44M.

    How many shares of ANTX are outstanding?

    AN2 Therapeutics has 46.11M shares outstanding. The count is up 52.31% from a year earlier.

    Does ANTX pay a dividend?

    No. AN2 Therapeutics does not pay a dividend.

    How much debt does ANTX have?

    AN2 Therapeutics has $0 of total debt and $20.21M of cash and equivalents, a net cash position of $20.21M.